It belongs beside it as a nonnegotiable if you want weight loss without unnecessary bone loss. What The Tirzepatide vs Liraglutide Bone Study Is Asking The TiLiBONE study follows people with obesity treated with tirzepatide or liraglutide and tracks body composition, bone mineral density, and bone turnover markers like CTX and P1NP. Investigators want to know whether tirzepatide and liraglutide affect bone metabolism differently after you adjust for how much weight someone actually loses, since rapid, large weight loss alone is known to cut BMD and raise fracture risk. TL;DR: This trial treats bone turnover as a primary outcome, which signals how seriously researchers now take bone health alongside fat loss in this class of drugs. What Bigger Reviews And RealWorld Data Say So Far Metaanalyses of GLP1 receptor agonists suggest no clear increase in fracture risk overall and even small improvements in BMD and bone turnover markers in some groups, though followup remains short. A large analysis in people with type 2 diabetes found that GLP1 users actually had a lower risk of osteoporosis than nonusers , hinting at possible boneprotective effects in that setting, but researchers still call for longer, higherquality trials. TL;DR: Tirzepatide has no proven direct osteoporosis signal yet, but the rapid weight loss and potential nutrient gaps mean anyone on GLP1/GIP therapy should plan for bone monitoring and protection, not just hope for the best
This process subsequently inhibits pattern recognition receptor (PRR) signaling and mitigates inflammatory responses [120, 121]
Physical activity and obesity: what we know and what we need to know*
Hypothalamic NPY-Y1R interacts with gonadal hormones in protecting female mice against obesity and neuroinflammation
Most bariatric surgeons recommend waiting at least 612 months post-surgery before introducing GLP-1 therapy, allowing the gastric adaptation phase to stabilize
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
